Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy

• Status: Withdrawn
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

People with epilepsy often experience problems with their memories and other thinking skills that get worse over time. The investigators hope to learn more about whether a drug called memantine can help improve or stabilize (keep the same) memory and other thought processes in people with epilepsy by blocking a chemical that is released in the brain during seizures. The investigators also want to see if memantine changes the frequency (how often) people with epilepsy have seizures. Memantine is currently approved by the United States Food and Drug Administration (FDA) for treatment of patients with Alzheimer's disease.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Michael A. Rogawski, MD, PhD; University of California, Davis
• Collaborator: Forest Laboratories
• Treatments: Memantine

Criteria

Inclusion Criteria:

1. Adult patients with temporal lobe epilepsy, aged 18-65

2. Seizure frequency of less than three per month

3. Stabilized treatment for epilepsy, including AEDs and vagus nerve stimulation

4. Intelligence Quotient of >70

5. Native English speaker (most of the neuropsychological/cognitive tests have yet to be translated and/or validated in non-English speaking populations. Thus, at this point we are limited to testing English speakers, only.)

6. Able to count seizures accurately and maintain a seizure diary

7. Recent AED levels performed within the last month within therapeutic range

Exclusion Criteria:

1. Progressive neurologic disease

2. Severe medical illness, including renal insufficiency

3. Severe depression, bipolar disease or psychosis

4. Pregnant or lactating women.